Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)

Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 31, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how well a specific test, called N-terminal-proB-type Natriuretic Peptide (NTproBNP), can help doctors determine if a patient’s pleural effusion (fluid buildup around the lungs) is related to heart failure. By measuring the levels of NTproBNP in the pleural fluid, researchers hope to improve the way heart failure-related fluid issues are diagnosed, which can help in providing better treatment.

To be eligible for this study, participants need to be adults aged 18 or older who are currently hospitalized due to heart failure and have a pleural effusion that requires fluid analysis. However, individuals with certain recent medical procedures or who cannot provide consent due to cognitive issues are excluded from participating. Those who join the trial can expect to undergo a procedure to collect pleural fluid, which will be analyzed alongside the NTproBNP test. This research is currently recruiting participants of all genders, and it aims to provide valuable insights into better diagnosing and managing heart-related fluid problems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients hospitalized for heart failure and pleural effusion
• • Pleural tapping indicated for pleural fluid analysis.
• • Aged 18 years old or above
• Exclusion Criteria:
• • History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space.
• • History of surgical decortication or pleurodesis in the ipsilateral pleural space.
• • Ipsilateral thoracic or cardiac surgery in the past 3 months.
• • Failure to obtain informed consent due to the patient's refusal or cognitive impairment.